|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-2.92/-0.14
|
Enterprise Value
4.58M
|
Balance Sheet |
Book Value Per Share
1.29
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
10.00K
|
Operating Revenue Per Share
1.83
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development. |